Bioray’s BR-111 cleared to enter clinic in China for ROR1-positive cancers

Feb. 10, 2025

Bioray Pharmaceutical Co. Ltd. has announced clinical trial clearance in China by the National Medical Products Administration (NMPA) for BR-111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.

BioWorld Science Regulatory Cancer Antibody-drug conjugate Immuno-oncology China NMPA

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 14, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...